BS_Z9ZS6ZS2
MPNST
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- MPNST
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- MPNST
- overall_survival_months
- 46.9119579500657
- age_years
- 17.395
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_9HA238XS | Neurofibroma | — | 0.950 |
| 2 | BS_49VCQD19 | Neurofibroma | — | 0.935 |
| 3 | A3874F0D-53A9-43C8-87EE-65C12C0F8135 | — | — | 0.929 |
| 4 | SRR12696731 | — | — | 0.924 |
| 5 | 7E4D42B3-FD9B-4184-A4A0-E52E45259428 | — | — | 0.921 |
| 6 | BS_RQSKD7PN | MPNST | — | 0.914 |
| 7 | BS_D5P6EZ1M | Schwannoma | — | 0.911 |
| 8 | R223 | — | — | 0.906 |
| 9 | BS_Y3G1X98S | Meningioma | — | 0.906 |
| 10 | BS_2W3NC4K1 | Neurofibroma | — | 0.906 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.640 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.635 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.548 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.513 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.502 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.493 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.479 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.464 | Idelalisib | — uncovered |
| APOPTOSIS | 0.463 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.445 | Inavolisib | — uncovered |
| COMPLEMENT | 0.414 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.376 | Remibrutinib | — uncovered |
| COAGULATION | 0.374 | Binimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.352 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.346 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.333 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.326 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.313 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.311 | Inavolisib | — uncovered |